Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393328 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Atazanavir 300 mg Capsule
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00393328 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants.
The verdict
NCT00393328, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.
Interventions
- DRUG Atazanavir + Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2006-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393328
The ClinicalTrials.gov registry entry for NCT00393328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atazanavir + Ritonavir is the first listed.
NCT00393328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00393328 about?
NCT00393328 is a clinical study titled "Bioequivalence Study of Atazanavir 300 mg Capsule". The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.
What is the current status of trial NCT00393328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2006-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00393328?
The interventions under investigation include: Atazanavir + Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00393328?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.